Non-cryopreserved peripheral blood stem cells autologous transplantation in multiple myeloma: Bicentric study

Jennane, Selim; Hasnaoui, Naoual; Mahtat, El Mehdi; Merimi, F.; Bougar, S.; Maaroufi, Hicham El; Belmekki, Abdelkader; Zafad, S.; Essakalli, M.; Mikdame, M.; Doghmi, Kamal

doi:10.1016/j.tracli.2020.03.006

Cited by 7 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, stem cell apheresis was successful at a median of only 1 or 2 days, which is advantageous for lymphoma patients, whose stem cell products need to be kept for over 1 week before reinfusion. Several studies reported that the duration of neutrophil engraftment was shorter in non-cryopreserved HSCT [ 4 , 5 ] In the present study, we also observed early neutrophil and platelet engraftment with lower rates of graft failure, which was possibly due to the high stem cell dose and high viability. We also observed earlier neutrophil and platelet engraftment in the myeloma patients compared to the lymphoma group, which resulted in fewer packed cell and platelet transfusions.…”

Section: Discussionsupporting

confidence: 81%

Non-Cryopreserved Peripheral Blood Stem Cell Graft for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma and Lymphoma Patients

et al. 2023

View full text Add to dashboard Cite

Background Hematopoietic stem cell transplantation (HSCT) using cryopreserved grafts is time-consuming, expensive treatment, and may associated with dimethyl sulfoxide (DMSO) toxicity. Here, we assess the clinical utility and safety of non-cryopreserved peripheral blood stem cell graft in autologous HSCT. Material/Methods Medical data of multiple myeloma or lymphoma patients who underwent autologous non-cryopreserved HSCT were reviewed. Results A total of 58 patients (40 myeloma and 18 lymphoma) were reviewed. The median myeloma and lymphoma CD34 + cell doses were 7.59 and 6.9 million/kg, respectively, with good viability after storage. The median times in neutrophil and platelet engraftment were 9 and 13 days and 11 and 14 days in myeloma and lymphoma, respectively. Only 5 patients in this cohort developed serious post-transplant complications. After transplantation, the cumulative incidence of relapse at 5 years was 34.4% in myeloma versus 19.1% in lymphoma patients. Notably, the mortality incidence rate rapidly increased within the first year and reached a plateau after 4 years, with cumulative incidence of 5.9% and 30.9% in myeloma and lymphoma, respectively. With a median follow-up time of 60 months, the median progression-free survival (PFS) and overall survival (OS) for lymphoma patients was 123.8 and 130 months, respectively. For the myeloma group, the median follow-up time was 38.6 months, the median PFS was 99.5 months, and OS was 157 months. Conclusions Non-cryopreserved HSCT is effective and safe. The long-term survival outcomes could be achieved by the shortening the duration of neutrophil and platelet engraftments and the complication rates are acceptable.

show abstract

Section: Discussionsupporting

confidence: 81%

Non-Cryopreserved Peripheral Blood Stem Cell Graft for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma and Lymphoma Patients

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Moreover, higher amounts of DMSO have also been previously related to the increased frequency of ≥ grade 2 AEs. 16 There is no standard storage time for refrigerated PBSC in studies with fresh autologous transplantation of MM, ranging from 24 to 144 h. 3,[18][19][20] Most studies comparing fresh and cryopreserved infusion have maintained fresh cells up to 48 h 3,4,11 and the increase of storage time must be clinically validated. 10 In our study, all fresh transplanted patients received PBSC after 72 h of cool storage.…”

Section: Resultsmentioning

confidence: 99%

“…There is no standard storage time for refrigerated PBSC in studies with fresh autologous transplantation of MM, ranging from 24 to 144 h 3,18–20 . Most studies comparing fresh and cryopreserved infusion have maintained fresh cells up to 48 h 3,4,11 and the increase of storage time must be clinically validated 10 .…”

Section: Discussionmentioning

confidence: 99%

Non‐cryopreserved peripheral blood stem cells as a safe and effective alternative for autologous transplantation in multiple myeloma

et al. 2022

View full text Add to dashboard Cite

Background: Autologous stem cell transplantation is the standard procedure for multiple myeloma and the grafts are usually cryopreserved. Previous studies reported advantages in the use of fresh peripheral blood stem cells (PBSC) autotransplantation compared to cryopreservation of the grafts. This study compared the transplant-related outcomes of two graft preservation methods: fresh storage (4°C/72 h) and cryopreservation (À80°C).

show abstract

“…L´utilisation de la bendamustine a été indiquée chez un malade en raison de non disponibilité de la carmustine à l´échelle nationale au cours d´une période donnée. Le Tableau 6 résume les principales caractéristiques de notre série en les comparants à certaines données de la littérature [ 3 , 6 , 18 ].…”

Section: Discussionunclassified

Bilan d´activité de l´unité de greffe de moelle osseuse du Centre Hospitalier Universitaires Mohamed VI de Marrakech, Maroc: 2012-2018

Loukhnati¹,

Lahlimi²,

Tazi³

2021

Pan Afr Med J

View full text Add to dashboard Cite

Introduction la greffe de cellules souches hématopoïétiques (GCSH) fait partie de l´arsenal de l´immunothérapie cellulaire à but curatif, elle est utilisée dans le traitement de plusieurs affections hématologiques malignes et non malignes ainsi que d´autres pathologies extra-hématologiques. Décrite depuis 1950 et introduite au Maroc depuis les années 2000, la GSCH reste encore jeune dans notre contexte avec plusieurs obstacles juridiques, financiers et organisationnels. L´objectif de notre travail est de rapporter l´expérience en matière de la greffe des cellules souches hématopoïétiques au sein du service d´hématologie clinique et de greffe de moelle osseuse du centre hospitalo-universitaire (CHU) Mohammed VI de Marrakech, étant un exemple d´un service des pays en voie de développement. Méthodes nous avons mené une étude rétrospective descriptive sur une durée de 7 ans. Résultats soixante-six GCSH ont été réalisées, le myélome multiple représente la première indication dans notre série avec 30 autogreffes. Dans notre série, Le taux de mortalité avoisine les 20%, celui de rechute est à 23% et celui des complications est à 38%. Nos résultats malgré les difficultés restent encourageants, avec un recul assez important. Conclusion des efforts restent à fournir pour améliorer les résultats de cette thérapie.

show abstract

Non-cryopreserved peripheral blood stem cells autologous transplantation in multiple myeloma: Bicentric study

Cited by 7 publications

References 32 publications

Non-Cryopreserved Peripheral Blood Stem Cell Graft for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma and Lymphoma Patients

Non-Cryopreserved Peripheral Blood Stem Cell Graft for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma and Lymphoma Patients

Non‐cryopreserved peripheral blood stem cells as a safe and effective alternative for autologous transplantation in multiple myeloma

Bilan d´activité de l´unité de greffe de moelle osseuse du Centre Hospitalier Universitaires Mohamed VI de Marrakech, Maroc: 2012-2018

Contact Info

Product

Resources

About